LH, BDX, DVA, COV And ESRX, Pushing Health Services Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 22 points (-0.1%) at 16,065 as of Monday, Dec. 2, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,030 issues advancing vs. 1,883 declining with 116 unchanged.

The Health Services industry currently sits up 0.1% versus the S&P 500, which is unchanged. On the negative front, top decliners within the industry include Parexel International Corporation ( PRXL), down 2.7%, and Grifols ( GRFS), down 0.7%. Top gainers within the industry include DexCom ( DXCM), up 5.3%, Acadia Healthcare Company ( ACHC), up 5.0%, Varian Medical Systems ( VAR), up 1.1% and Humana ( HUM), up 1.0%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Laboratory Corporation of America Holdings ( LH) is one of the companies pushing the Health Services industry lower today. As of noon trading, Laboratory Corporation of America Holdings is down $1.34 (-1.3%) to $100.51 on heavy volume. Thus far, 623,212 shares of Laboratory Corporation of America Holdings exchanged hands as compared to its average daily volume of 660,100 shares. The stock has ranged in price between $100.06-$101.61 after having opened the day at $101.46 as compared to the previous trading day's close of $101.85.

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. Laboratory Corporation of America Holdings has a market cap of $8.9 billion and is part of the health care sector. The company has a P/E ratio of 16.8, below the S&P 500 P/E ratio of 17.7. Shares are up 17.6% year to date as of the close of trading on Friday. Currently there are 3 analysts that rate Laboratory Corporation of America Holdings a buy, 2 analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Laboratory Corporation of America Holdings as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, revenue growth, notable return on equity, increase in stock price during the past year and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Laboratory Corporation of America Holdings Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Becton Dickinson ( BDX) is down $0.65 (-0.6%) to $107.94 on average volume. Thus far, 362,749 shares of Becton Dickinson exchanged hands as compared to its average daily volume of 673,500 shares. The stock has ranged in price between $107.90-$108.88 after having opened the day at $108.76 as compared to the previous trading day's close of $108.59.

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company's BD Medical segment produces medical devices that are used in various healthcare settings. Becton Dickinson has a market cap of $21.2 billion and is part of the health care sector. The company has a P/E ratio of 23.3, above the S&P 500 P/E ratio of 17.7. Shares are up 39.3% year to date as of the close of trading on Friday. Currently there are 6 analysts that rate Becton Dickinson a buy, 4 analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Becton Dickinson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Becton Dickinson Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, DaVita HealthCare Partners ( DVA) is down $0.40 (-0.7%) to $59.15 on light volume. Thus far, 546,071 shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $59.13-$59.67 after having opened the day at $59.46 as compared to the previous trading day's close of $59.55.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. DaVita HealthCare Partners has a market cap of $12.7 billion and is part of the health care sector. The company has a P/E ratio of 22.5, above the S&P 500 P/E ratio of 17.7. Shares are up 8.3% year to date as of the close of trading on Friday. Currently there are 7 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full DaVita HealthCare Partners Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Covidien ( COV) is down $0.42 (-0.6%) to $67.84 on light volume. Thus far, 787,584 shares of Covidien exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $67.57-$68.07 after having opened the day at $67.64 as compared to the previous trading day's close of $68.26.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $31.0 billion and is part of the health care sector. The company has a P/E ratio of 20.1, above the S&P 500 P/E ratio of 17.7. Shares are up 18.5% year to date as of the close of trading on Friday. Currently there are 14 analysts that rate Covidien a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Covidien Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Express Scripts ( ESRX) is down $0.41 (-0.6%) to $66.94 on light volume. Thus far, 1.2 million shares of Express Scripts exchanged hands as compared to its average daily volume of 5.2 million shares. The stock has ranged in price between $66.68-$67.37 after having opened the day at $67.32 as compared to the previous trading day's close of $67.35.

Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services primarily in the United States and Canada. It offers healthcare management and administration services on behalf of its clients. Express Scripts has a market cap of $54.4 billion and is part of the health care sector. The company has a P/E ratio of 29.2, above the S&P 500 P/E ratio of 17.7. Shares are up 25.0% year to date as of the close of trading on Friday. Currently there are 13 analysts that rate Express Scripts a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Express Scripts Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Centene, LabCorp Among Healthcare Stock Gainers

Centene, LabCorp Among Healthcare Stock Gainers

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Amid M&A Buzz, LabCorp CEO Says Deal Pipeline 'Very Healthy'

Amid M&A Buzz, LabCorp CEO Says Deal Pipeline 'Very Healthy'

INC Research Holdings Seen as Likely LabCorp. Takeover Target

INC Research Holdings Seen as Likely LabCorp. Takeover Target

5 Big Stocks to Buy for Big Gains

5 Big Stocks to Buy for Big Gains